Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

Takeda presents positive results from trial of chronic kidney disease treatment

June 10, 2025 Research and Development European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney disease

Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A …
News
Publishing image

ANGLE’s Parsortix system used in new cancer biology research

June 10, 2025 Medical Communications, Research and Development Angle, Oncology, Parsortix system, R&D, biotech, oncology, scientific journals

ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour cell (CTC) harvesting system in …
News

Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research

June 10, 2025 Conferencing, Events & Incentives, Interactive Conferences, Medical Communications, Research and Development, Sales and Marketing Guillain-Barré syndrome, Hansa Biopharma, Immunology, Neurology, investor event

Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 June 2025. The webcast aims …
News

Vertex presents promising new data from cystic fibrosis trials

June 9, 2025 Medical Communications, Research and Development European Cystic Fibrosis Conference, Rare Diseases, Vertex, clinical trial, cystic fibrosis

Vertex Pharmaceuticals has presented new data showing the clinical and quality-of-life benefits of its cystic fibrosis (CF) therapies, particularly Alyftrek …
News
hsm_mobile_clinical_trial_istock-872676342

Corcept reports survival benefit in ALS trial of dazucorilant despite missing primary endpoint

June 9, 2025 Research and Development Corcept Therapeutics, European Network to Cure ALS (ENCALS), Neurology, amyotrophic lateral sclerosis, clinical trial

Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients with amyotrophic lateral sclerosis (ALS), …
News
baby-2416718_1280

Study into treatment for rare condition in premature infants launches globally

June 9, 2025 Research and Development Chiesi Farmaceutici, Elgan Pharma, Gastrointestinal tract, Paediatrics, clinical trial, intestinal malabsorption, premature infant health

Elgan Pharma, specialising in neonatology, and Italy-based biopharma, Chiesi Farmaceutici, have announced the dosing of the first participating infants in …
News
laboratory-testing-az

Trial into rare genetic disease Werner syndrome reports promising results

June 6, 2025 Research and Development Chiba University, Niagen Bioscience, Rare Diseases, Werner Syndrome, clinical trial, rare genetic disease

Researchers at Chiba University, Japan, alongside Niagen Bioscience, have reported successful results from the world’s first trial of nicotinamide riboside …
News

Osivax reaches key milestone in phase 2a trial for broad-spectrum flu vaccine

June 6, 2025 Research and Development Ghent University Hospital, Osivax, Vaccine, Virology, clinical trial, influenza a

Osivax has announced the completion of patient visits in its phase 2a trial evaluating a booster dose of OVX836, a …
News

BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours

June 6, 2025 Research and Development BioNTech, Oncology, bispecific antibody treatment, bristol myers squibb, oncology, partnership

BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to …
News

Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy

June 5, 2025 Research and Development European Commission, Evrysdi, Neurology, Roche, european union, neuromuscular condition, spinal muscular atrophy (SMA)

Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and …
News
lab

Study links COVID-19 and some vaccines to increased risk of rare neurological condition

June 5, 2025 Medical Communications, Medical Education, Medical/ Scientific Writing, Research and Development COVID-19, COVID-19 vaccine, Guillain-Barré Syndrome (GBS), Neurology, Virology, adenoviral vector vaccines, mRNA-based vaccines, medical study, neurological condition

An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral …
News

EU regulatory momentum could catalyse clinical trial innovation

June 5, 2025 Regulatory Affairs, Research and Development AI, Corporate, EU regulation, Hospital Management, Pharmacy, Veeva Systems

Dr Werner Engelbrecht at Veeva Systems discusses how compliance can be turned into a competitive advantage with connected platforms and …
Feature

NIPRO introduces LiniXia water treatment system for dialysis clinics

June 4, 2025 Research and Development European Renal Association (ERA) Congress, LiniXia, LiniXia PRO, NIPRO, Nephrology, dialysis clinics, water treatment

Japan-based biopharma, NIPRO, has launched LiniXia, a new reverse osmosis (RO) water treatment system for haemodialysis. It was unveiled at …
News

Evosep launches high-throughput proteomics platform Evosep Eno

June 4, 2025 Business Services, Mergers and Acquisitions, Research and Development, Translation Services Evosep, Pharmacy, biotech platform

Evosep has launched Evosep Eno, a new high-throughput separation platform designed to support next-generation workflows in liquid chromatography-mass spectrometry (LC-MS)-based …
News
cream-4713579_1920

LEO Pharma initiates phase 2a trial of delgocitinib cream for rare skin condition

June 3, 2025 Research and Development Dermatology, LEO Pharma, Skin, clinical trial, delgocitinib cream, rare skin condition

LEO Pharma has initiated a phase 2a trial investigating delgocitinib cream in adults with mild-to-severe palmoplantar pustulosis (PPP). The DELTA …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025